Please assess the completion status of the following clinical trial:

Trial Title: Registry to Measure the Impact of Adding Genomic Testing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (\< or equal to 12 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics:~* PSA less than or equal to 10 ng/dl and~* Gleason's 7 (4+3 or 3+4) or Gleason's 6 and~* Age greater than 55 years old and~* Clinical Stage T1 or T2~* Clinically localized (no evidence on clinical or imaging studies of advanced disease).~* No hormonal therapy including luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.~Exclusion Criteria:~- Known history of hypogonadism

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).